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Introduction
Chimeric antigen receptors (CARs) are artificial molecules 
that redirect the specificity of T cells to predetermined anti-
gens.1–3 The prototype CAR was first described by Eshhar 
and colleagues in 1993, in which specific activation and tar-
geting of T cells was mediated through molecules consisting 
of a target-antigen–specific antibody domain and the γ- or 
ζ-signaling subunits of the Fc epsilon receptor or T cell recep-
tor, respectively.2 Since then, many groups have devised 
CAR molecules with single tumor-directed specificities and 
enhanced signaling endodomains;4–6 CAR T cell-based clini-
cal trials are currently underway, with some highly promising 
early results.6–10
Rendering an individual T cell bispecific could have sub-
stantial functional implications that would likely translate into 
therapeutic benefits. Downregulation or mutation of target 
antigens is commonly observed in cancer cells, creating 
antigen-loss escape variants; a bispecific T cell could thus 
offset tumor escape.11 Furthermore, this bispecificity could 
enable simultaneous targeting of tumor cells and elements 
in the tumor microenvironment thereby augmenting T cell 
activation and function by increasing avidity and by broaden-
ing their therapeutic reach.12 To accomplish such bispecificity, 
we constructed a CAR in which two distinct antigen recogni-
tion domains are present in tandem on a single transgenic 
receptor.
The folding of an amino acid chain into highly organized, 
biologically functional three-dimensional protein structures, 
such as a CAR, continues to be a challenge in the design 
of novel protein molecules.13 In particular, protein misfold-
ing, mispairing, and malfunction/dysfunction have tradition-
ally impeded the wide scale production of molecules with 
multiple specificities.14 Advances in computational model-
ing methods, through characterization of the underlying 
energy landscapes as well as the dynamics of the polypep-
tide chains, have made structure prediction, analysis and 
design of a novel protein molecule, such as a tandem CAR, 
more feasible.15,16 Furthermore, docking routines have 
recently made it possible to predict, with high accuracy, the 
interface between two candidate molecules in a manner 
that could help to elucidate their functionality.17
We used computational modeling tools to predict the func-
tionality of a novel single CAR molecule that can mediate 
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Targeted T cells are emerging as effective non-toxic therapies for cancer. Multiple elements, however, contribute to the 
overall pathogenesis of cancer through both distinct and redundant mechanisms. Hence, targeting multiple cancer-specific 
markers simultaneously could result in better therapeutic efficacy. We created a functional chimeric antigen receptor—
the TanCAR, a novel artificial molecule that mediates bispecific activation and targeting of T cells. We demonstrate 
the feasibility of cumulative integration of structure and docking simulation data using computational tools to interrogate 
the design and predict the functionality of such a complex bispecific molecule. Our prototype TanCAR induced distinct 
T cell reactivity against each of two tumor restricted antigens, and produced synergistic enhancement of effector functions 
when both antigens were simultaneously encountered. Furthermore, the TanCAR preserved the cytolytic ability of 
T cells upon loss of one of the target molecules and better controlled established experimental tumors by recognition 
of both targets in an animal disease model. This proof-of-concept approach can be used to increase the specificity of 
effector cells for malignant versus normal target cells, to offset antigen escape or to allow for targeting the tumor and its 
microenvironment.
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bispecific activation and targeting of T cells. This tandem 
CAR (TanCAR) recognizes each target molecule individually 
and facilitates synergistic activation and functionality when 
both are encountered simultaneously. Such findings could 
have important therapeutic implications.
Results
Requirements for a bispecific “tandem” CAR: The 
TanCAR
We designed a proof-of-concept molecule, the TanCAR, 
to simultaneously target the B-cell antigen CD19 and the 
human epidermal growth factor receptor 2 (HER2/neu; also 
known as ErbB-2, CD340, and p185).
The extracellular domain of the TanCAR was designed to 
include a CD19-specific single chain antibody variable frag-
ment (scFv) followed by a Gly-Ser linker, a HER2-specific 
scFv (FRP5) and another Gly-Ser tandem repeat hinge.18 
Gly-Ser tandem repeats are highly flexible and non-cleavable 
thus would allow for near-free motion of the TanCAR subunits. 
Because of the respective lengths of HER2 (632aa/125Å) and 
CD19 (280aa/65Å) extracellular domains and the  knowledge 
that FRP5 binds to the distal-most 4 loops of HER2 (W. Wels; 
unpublished data), we placed HER2-scFv in the juxta-mem-
brane position and the CD19-scFv in the distal position to 
allow for more relaxed and potentially simultaneous binding. 
The intracytoplasmic domain of the proposed TanCAR mol-
ecule consists of a CD28/CD3-ζ signaling moiety, as previ-
ously described (Figure 1).19
Computational docking of the proposed TanCAR design 
to target molecules
Predictive molecular modeling was used to interrogate the 
hypothetical TanCAR structure and provide rational basis for 
constructing a potentially functional molecule. To determine 
if the aforementioned molecular arrangement was possible, 
we created a TanCAR structural model using the protein-
structure modeling webserver, ModWeb.20 Four structural 
templates with >58% sequence identity were identified, from 
which a model for residues 39–285 of TanCAR was con-
structed (Figure 2a).
The next step was to assess how this TanCAR might 
interact with CD19 and HER2, individually. Although the 
structure of HER2 is known,21 no structure of CD19 is cur-
rently available. As such, a homology model for CD19 was 
generated using the 3MJG crystal structure as a structural 
template for residues 1–272 within the Modeller software.22 
Using a combination of Patchdock and FireDock,23,24 auto-
mated tools for docking and refining two structures based on 
shape complementarity, the docking of HER2- and CD19-
scFv’s to their respective target molecules was simulated 
 (Figure 2b,c). Thereafter, the whole TanCAR extracellular-
domain model was docked pairwise to both structures, indi-
vidually  (Figure 2d,e). Results from the pairwise dockings 
were screened based on the overall score and agreement 
with known interaction sites from peptide spotting experi-
ments in the case of HER2 (Supplementary Figure S1).25
From the in silico docking of these molecules, it appeared 
that the potential interactions of TanCAR with the target mol-
ecules could accommodate the intended bispecificity, and as 
such, we used this arrangement as an initial model to explore 
the ability of TanCAR to interact with the target molecules 
individually.
Construction, delivery, and expression of the TanCAR-
encoding transgene
The modeled design of the TanCAR extracellular domain, 
composed of the CD19- and HER2-scFv fragments in tandem 
and separated by a linker, was assembled on Clone Man-
ager, modified to introduce desired and remove unwanted 
restriction enzyme sites and optimized for maximum protein 
production using GeneOptimizer software.26 This exodomain 
was custom synthesized as a DNA fragment and subcloned 
in frame into an SFG retroviral vector containing a short 
hinge, CD28 transmembrane and signaling domains and 
the signaling domain of the CD3ζ-chain (Figure 3a).27 The 
resulting TanCAR transgene was then expressed in 293T 
cells as previously described.28 By flow cytometry, we deter-
mined ~89% and ~59% of 293T cells to surface express the 
TanCAR using Fab-specific antibody (binds both CD19-scFv 
and HER2-scFv) and a HER2-Fc protein (binds HER2-scFv 
only), respectively (Supplementary Figure S2 and Figure 
3b). Similarly, >70% of T cells transduced using the 293T 
cells retroviral supernatant surface expressed the TanCAR 
(Figure 3c). Specific detection of the juxta-membrane HER2-
scFv confirmed that the surface expression of the TanCAR 
extracellular domain in its entirety.
TanCAR-expressing T cells distinctly recognize each 
 target antigen
To test the dual functionality of the TanCAR T cells against 
CD19 and HER2, we first confirmed surface expression of 
these target antigens on a panel of human cancer cell lines 
using flow cytometry. Raji Burkitt lymphoma cells uniformly 
expressed the B-lineage marker CD19 but lacked detect-
able HER2 (Figure 4a).6 Conversely, Daoy medulloblas-
toma cells uniformly expressed HER2 but did not express 
CD19.28 MDA-MB-468 breast cancer cells were negative for 
both.28
Figure 1 Designing a bispecific tandem chimeric antigen 
receptor (TanCAR) molecule. Representation of the proposed 
chimeric antigen receptor molecule extracellular domains engaging 
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Figure 2 Docking platforms predict favorable binding potential of TanCAR to target molecules. Compilation of structure and docking 
data of (a) hypothetical structure of both FRP5-derived scFv and the CD19-specific scFv joined with a 20 amino acid Gly-Ser linker; (b) 
most favorable docking models of FRP5-derived scFv and the distal 200 amino acid residues of the extracellular domain of HER2; (c) most 
favorable docking models of CD19-scFv and the extracellular domain of CD19, and combined docking of (d) HER2 and (e) CD19 and the 
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In 4-hour 51Cr-release assays, TanCAR T cells recognized 
and killed HER2-expressing Daoy cells but not MDA-MB-468 
cells. Non-transduced T cells from the same donor had no 
lytic activity, excluding an allogeneic response. Up to 95% of 
lysis could be blocked by soluble HER2 protein (Figure 4b), 
indicating that specific recognition occurred due to HER2 
binding. Similarly, CD19-expressing Raji cells were killed by 
TanCAR T cells but not CD19 negative MDA-MB-468 cells. 
CD19-specific MAb 4G7 blocked cytolytic activity against 
Raji cells by up to 70% (Figure 4c).
In cocultures, TanCAR T cells secreted Interferon-γ (IFN-γ) 
and Interleukin-2 (IL-2) upon encountering HER2- or CD19-
positive target cells. No cytokines were secreted in coculture 
with MDA-MB-468 (Figure 4d). These results indicate that 
TanCAR is bispecific for CD19 and HER2, and mediates 
activation and targeting of T cells upon encounter of either 
antigen alone.
Enhanced functionality upon simultaneous encounter 
of both target antigens and preserved TanCAR T-cell–
induced cytolysis in a model of antigen loss
To investigate the hypothetical potential for simultaneous 
binding of the TanCAR molecule to both target antigens we 
visualized and aligned the pairwise dockings in UCSF’s Chi-
mera and evaluated the ensemble docking for global energy, 
agreement with interaction sites and steric clashes.29 Indeed, 
this composite algorithm yielded a sterically possible favor-
able docking combination in which HER2 and CD19 struc-
tures were both bound to the TanCAR without any clashes 
(Figure 5a). Based on this docking model, both the HER2 
and CD19 are arranged such that their N-termini are essen-
tially orientated in the same direction; hypothetically, this is 
the tumor cell direction. As the CD19 structure is ~50% of 
the size of HER2, there is a separation of ~93Å between 
the N-termini of both molecules. Differences in orientation of 
CD19 and HER2 along the cell membrane, as well as varia-
tions in the cell membrane itself, could account for the differ-
ence between the size and orientation of the receptors but 
would still allow for the simultaneous docking of both HER2 
and CD19 to the TanCAR.
To study the kinetics of activation of TanCAR T cells in vitro 
and in vivo in the presence of both target molecules, we used 
a tetracycline-inducible system (Tet-On 3G) to condition-
ally express a truncated non-signaling CD19 molecule on 
Daoy cells (Daoy.TET.CD19).30 In the presence of doxycy-
cline (DOX+), 60–85% of the endogenously HER2-positive 
Daoy.TET.CD19 cells expressed CD19 and the reporter 
gene mCherry (Supplementary Figure S3a). In cytotoxicity 
assays, we saw consistently higher killing after the induction 
of CD19 for all tumor/T-cell ratios tested. This enhancement 
of cytolysis followed an exponential trend with a higher order 
equation, an effect that became more evident at higher 
tumor/T cell ratios (Figure 5b). This indicates a synergistic 
effect of simultaneous recognition of both target antigens on 
the ability of T cells to lyse target cells. Consistent with these 
results, we observed fourfold increase (P < 0.01) in IFN-γ 
secretion upon induction of CD19 (Figure 5c).
Downregulation or mutation of target antigens is a com-
mon process in cancer cells creating antigen-loss escape 
variants. Such variants are responsible for persistence of 
tumor cells at very low frequencies, and their outgrowth cul-
minates in relapse. We simulated the downregulation of a 
targeted antigen by blocking HER2 recognition in CD19-
induced (DOX+) Daoy.TET.CD19 cells using a soluble HER2 
fragment. Although the competitor successfully impaired 
HER2-mediated killing in these cells (up to 90%), bispecific 
TanCAR T cells were less affected by soluble HER2 frag-
ment blocking because of maintained recognition of CD19 
(Figure 5d).
Simultaneous targeting of two antigens enhances the 
in vivo antitumor activity of TanCAR T cells
We used a xenograft model to assess the potential advan-
tage of simultaneously targeting two antigens in established 
tumors. We inoculated Daoy.TET.CD19 xenografts in the 
flanks of SCID mice. The induction of CD19 by intraperitoneal 
doxycycline was confirmed in a subset of animals (Supple-
mentary Figure S3b). The tumors were allowed to establish 
Figure 3 Construction and surface expression of the TanCAR 
molecule. (a) pSFG vector construct encoding the TanCAR; (b) 
detection of the surface expression of the TanCAR using a Fab-
specific antibody and FRP5-specific HER2-Fc protein on 293T cells; 
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for 3 weeks, after which animals were randomly assigned 
into four groups. All four groups of animals had similar tumor 
volumes after randomization (mean tumor volume 94 µl; 
SD 28 µl). Two groups received intraperitoneal doxycycline 
(DOX+) whereas the other two received phosphate-buffered 
saline (PBS; DOX−). Within DOX+ and DOX− groups, five 
animals each received one intratumoral injection of 10,000 
TanCAR T cells/µl tumor volume. Administration of PBS or 
doxycycline alone induced minimal or no alteration of the 
tumor growth pattern. By contrast, TanCAR T cells resulted 
in significant delay in tumor progression that was further 
increased by induction of CD19 (Figure 6a). Kaplan–Meier 
survival studies after 60 days from treatments showed that 
mice administered PBS with and without doxycycline had a 
median survival of 28 and 31 days, respectively. In contrast, 
mice treated with TanCAR T cells had a median survival of 44 
days (P < 0.01). Furthermore, mice administered TanCAR T 
cells and doxycycline had a median survival of >60 days with 
50% of the mice surviving >80 days (P < 0.001; Figure 6b). 
Hence, simultaneous recognition of two antigens enhanced 
the in vivo antitumor activity of adoptively transferred Tan-
CAR T cells.
Discussion
We created a functional CAR, the TanCAR, a novel artificial 
molecule that mediates bispecific activation and targeting of T 
cells. We demonstrated the feasibility of cumulative integration 
of structure and docking simulation data using computational 
tools to interrogate the design and predict the functionality 
of such a complex bispecific molecule. Our prototype Tan-
CAR induced distinct T cell reactivity against each of two 
target molecules, and produced synergistic enhancement of 
effector functions when both antigens were simultaneously 
encountered. Furthermore, the TanCAR preserved the cyto-
lytic ability of T cells upon loss of one of the target molecules 
and better controlled established experimental tumors by rec-
ognition of both targets in an animal disease model.
An approach using effector cells with multiple specificities 
could have a number of benefits as cancer therapy. First, 
simultaneous targeting of multiple tumor antigens could 
overcome antigen escape by providing an alternative killing 
pathway if there is antigen downregulation or deletion. Sec-
ond, such effector cells would exhibit a broader spectrum of 
specificities allowing for targeting of heterogeneous antigens, 
such as those present on the tumor cells and within the tumor 
microenvironment, thereby enhancing tumor control by dam-
aging the tumor complex. Lastly, the simultaneous encounter 
of several antigens should enhance T cell activation through 
increased avidity, a particular benefit when tumors express 
only modest levels of individual antigens.12,31
The potential benefits of bispecific antibodies and related 
molecules have led to an intensive investigation and defi-
nite successes of various designs and specificities. Indeed, 
Figure 4 The TanCAR T cells distinctly recognize individual 
target molecules. (a) Flow cytometric analysis of the surface 
expression of the target antigens, HER2 and CD19, on a panel of 
human cancer cell lines used for functional testing; (b) cytotoxicity 
assay showing recognition and killing of HER2-positive Daoy cells 
and efficient blocking of this lysis using a soluble HER2 fragment; (c) 
similarly, TanCAR T cells recognized CD19-positive Raji cells and 
this lysis was blocked using the CD19 Ab 4G7; (d) in cocultures, 
TanCAR T cells secreted IFN-γ as well as IL-2 upon encounter of 
HER2- and CD19-positive target cell above the non-transduced 
T-cell control (NT). No cytokines were secreted in coculture with the 
HER2- and CD19-null target cell MDA-MB-468. (b–d) Shown are 
representative plots of three or more experiments done in triplicates.
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Blinatumomab, a CD3/CD19-bispecific antibody, has been 
shown in a Phase I/II trial to induce objective responses in 
non-Hodgkin lymphoma patients.32 Unfortunately, the wider 
scale therapeutic use of bispecific antibodies has faced 
obstacles related to manufacturing feasibility and limitations 
related to pharmacokinetics and stability.33 Tandem-scFv, 
diabodies, two-in-one antibodies, and dual variable domain 
antibodies were introduced as novel designs that were able 
to overcome some of these limitations but still suffer from 
residual shortcomings of antibody-based approaches.33–36 
Antibodies, unlike T cells, do not actively migrate through 
microvascular-walls or penetrate the core of solid tumors to 
exert their antitumor activity and usually have no access to 
the neuraxis, a common sanctuary for cancer cells.37,38 Fur-
thermore, in the context of modest expression of target anti-
gens, antibodies exhibit limited efficacy.31,39 T cells expressing 
antibody-derived CARs have been shown to overcome such 
limitations.31,40
Our group previously redirected the specificity of T cells to 
two distinct entities by grafting tumor-restricted antigen-spe-
cific CARs onto T cells whose native receptor was specific for 
latent-virus antigens. Thus, we grafted EBV-specific cytotoxic 
T cells (EBV-CTLs) with a GD2-specific CAR to treat Neuro-
blastoma, whereas CMV.CTLs were grafted with HER2-spe-
cific CARs to treat Glioblastoma.7 The intent was to enable 
CAR expressing CTLs to receive optimal costimulation after 
native-receptor engagement of viral antigens on professional 
antigen presenting cells, and thereby enhance their in vivo 
survival in these first-in-man studies.7,41
This work describes the first rationally designed artificial 
molecule to render a T cell bispecific. We demonstrate syn-
ergistic killing which should further enhance function and 
resistance against antigen loss. A combination of these 
approaches may also be feasible by grafting a TanCAR to 
a latent-virus–specific CTL, thereby providing a trispecific 
T cell with enhanced in vivo survival. The TanCAR could 
be further modified to incorporate additional costimulatory 
endodomains to enhance the degree of T cell activation and 
persistence.6,10
Though much progress has been made, designing novel 
protein molecules with correct protein folds is still very chal-
lenging.13,14 Indeed, Patel et al. described, in 2000, T cell 
Figure 5 Enhanced cytolytic function upon simultaneous recognition of two antigens and preserved TanCAR T cell-induced 
cytolysis in a model of antigen loss. (a) Collective modeling of the simultaneous docking of the TanCAR to both HER2 and CD19. (b) In 
cytotoxicity assays, we saw consistently higher killing after the induction of CD19 at various tumor to T cell ratios. This was synergistic; with 
an exponential trend following a higher order equation; and was more prominent in higher tumor to T cell ratios (right panel). (c) Similarly, 
induction of CD19 (DOX+) in Daoy.TET.CD19 and T cell cocultures resulted in a more than fourfold increase in IFN-γ release as detected by 
ELISA (P  < 0.01). (d) We modeled the scenario in which tumor cells downregulate the target antigen, by blocking HER2 in CD19-induced 
(DOX+) and CD19 null (DOX−) Daoy.TET.CD19 cells using a soluble HER2 fragment (s.HER2). Although soluble HER2 successfully induced 
substantial blocking of HER2-mediated killing in DOX− cells at various tumor to T cell ratios, it resulted only in a partial decrease in the cytolytic 
effect of TanCAR T cells in DOX+. P values were significant at T cell to tumor cell ratios of 1:20, 1:10, and 1:5. Shown are representative plots 
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products expressing four empiric designs of anti-tumoral 
antigen bispecific chimeric immune receptors one of which 
lysed both CEA- and TAG-72-expressing targets and did not 
kill antigen-negative targets or target cells expressing other 
members of the CEA family.42 However, the recent advances 
in computational modeling and protein–protein docking make 
structure design and analysis of a novel protein, such as the 
aforementioned tandem CAR, more feasible.15,16 We used 
such tools, in a staged methodology, to profile the energy 
landscapes as well as the dynamics of the polypeptide chains 
in all stages of the folding process, in an attempt to predict 
functionality of this molecule. We reasoned that although 
CD19 and HER2 are not naturally coexpressed on normal 
or malignant cells, using them as targets would allow us to 
directly test the effects of binding one or both target antigens 
and the consequences of such binding on T cell activation 
and target cell killing. Both molecules are well characterized 
as targets and are in multiple clinical trials using CAR T cells. 
Furthermore, a crystal structure of HER2 was available.21 
Although the structure of CD19 is unknown, several  potential 
structural templates, with relatively high sequence similar-
ity, are available for constructing a CD19 homolog model. 
Coupled with a model of TanCAR, it is possible to reliably 
assess its docking potential to these target molecules.
The TanCAR model was produced from several closely 
related structures (>50% identity between the sequences 
of interest and the template structures), demonstrating that 
computational modeling is a useful tool in the construction 
of such complex molecules by interrogating their functional 
structure and predicting their functionality. However, in the 
proposed model, the Gly-Ser linker has no structural tem-
plate; therefore, the exact structure of this loop and the orien-
tations of the two TanCAR domains with respect to each other 
most likely exhibit some degree of variation. It is conceivable 
that, whereas unbound, TanCAR remains as a soluble, com-
pact, globular protein. When bound to HER2 and CD19, ste-
ric forces may cause the two domains to separate, remaining 
tethered to each other through an extended conformation 
of the Gly-Ser linker. In an extended conformation, this loop 
could help resolve some of the differences in “height” of the 
two target molecules on the surface of the cell. Regardless of 
the conformation of the loop, the interface proposed by our 
docking is compatible with either a compact or extended form 
of the linker. In this respect, the achievement of a definite 
Figure 6 Simultaneous targeting of two antigens enhances the in vivo antitumor activity of adoptively transferred TanCAR T cells. 
(a) Daoy.TET.CD19 xenografts were established for 3 weeks in the flanks of SCID mice, and then animals were randomized into four groups. 
Administration of PBS into the tumor and/or systemic doxycycline induced minimal or no alteration of the tumor growth pattern. By contrast, 
treatment with TanCAR T cells resulted in a significant delay in tumor progression that was further enhanced by induction of CD19 expression 
in the DOX+ group. (b) Kaplan–Meier survival curve: analysis performed 60 days after PBS or T-cells injection. Mice treated with TanCAR T 
cells had a significantly longer survival probability in comparison with control mice. Furthermore, induction of CD19 by the administration of 
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low energy model that1 incorporates docking routines of both 
scFv’s to their respective molecules, simultaneously, while2 
maintaining the polarity and distance of the target versus 
effector ends of all three molecules was an indicator of the 
correct orientation of the proposed design. Using alternative 
positions of the scFv’s or different lengths of the linker seg-
ment failed to achieve these goals and thus a collective dock-
ing model was not generable. This TanCAR design with the 
FRP5 in the juxta-membrane position and a 20 amino acid 
Gly-Ser linker was then expressed in T cells and analyzed for 
its biological activity.
Indeed, when the hypothetical molecule was physically 
generated and tested, our results corroborated the predictive 
modeling. The surface expression of the TanCAR exodomain 
in its entirety was validated by detection of the juxta-mem-
brane HER2-scFv. The proper folding and retention of the 
VL and VH stereo-orientation for HER2-scFv and CD19-scFv 
was evident in the specific recognition and distinct lysis by 
TanCAR T cells of tumor cells expressing these target mol-
ecules and the blockade of this lysis with the respective com-
petitors. Failure to block the cytolytic effect against tumor 
cells expressing both targets using soluble HER2 indicated 
that the dual functionality of TanCAR T cells allowed for per-
sistence of their effector functions despite antigen loss. This 
redundancy in function would be favorable in such a scenario. 
Lastly, the enhancement of cytolysis upon induction of CD19 
in HER2-expressing targets indicated synergistic dynamics 
that further translated into improved tumor control in an ani-
mal model using a relatively small dose of T cells. These find-
ings point to the potential of TanCAR T cells for therapeutic 
application in human disease.
With the enhanced activation of T cells comes the risk of 
adverse events related to recognition of modestly expressed 
antigens resulting in off-target effects. Although our group 
has recently shown that it is possible to quickly eliminate 
adoptively transferred T cells in case of adverse events by 
inducing apoptosis through a suicide gene43, TanCAR mole-
cules could be conceptually used to “bar code” tumor cells—
wherein only dual-antigen expressers are killed. Similarly, 
other groups have used a functionally bipartite CAR molecule 
that conditionally triggers sufficient T cell activation only on 
simultaneous engagement of two distinct tumor antigens.44 
Alternatively, TanCARs themselves could also be engineered 
to include antibody recognizable moieties that, in the advent 
of adverse events, would allow for the rapid elimination of 
TanCAR T cells.
In summary, we here describe a novel bispecific CAR 
 molecule—termed TanCAR. TanCAR induced bispecific 
activation of T cells and exhibited potent effector functions 
against individual target antigens as well as synergistic 
enhancement of functionality upon simultaneous engage-
ment of both. Preclinical studies of TanCAR T cells in an ani-
mal tumor model demonstrated its potential for therapeutic 
application in human disease.
Materials and methods
Blood donors and tumor cell lines. Studies were performed 
on Baylor College of Medicine (BCM) IRB-approved protocols 
and informed consent was obtained from all blood donors. 
The tumor lines Daoy, Raji, and MDA-MB-468 were pur-
chased from ATCC (Manassas, VA). All cell lines were grown 
in DMEM (Invitrogen, Carlsbad, CA) with 10% fetal calf serum 
(HyClone, Logan, UT), with 2 mmol/l GlutaMAX-I, 1.5 g/l 
sodium bicarbonate and 1.0 mmol/l sodium pyruvate (Invi-
trogen). T cells derived from peripheral blood mononuclear 
cells were activated on CD3/CD28 antibody-coated plates 
and were expanded in IL-2 (100 U/ml)-containing RPMI1640 
with 10% fetal calf serum and 2 mmol/l GlutaMAX-I.
Protein structure modeling and docking. A model for the 
bispecific CAR was constructed using ModWeb, an auto-
mated web server for protein-structure modeling.20 The 
full-length TanCAR sequence was submitted to the Mod-
Web server, which identified the two antibody-like fragment 
domains. 1OP345 was identified as a candidate structural 
template for residues 40–146 (59.81% sequence identity) 
and 1F3R46 as a candidate structural template for residues 
167–329 (58.90% sequence identity). Additional structural 
templates, 3ESV (64.76% sequence identity) and 2KH2 
(59.51% sequence identity),47,48 were also identified covering 
residues 38–285. From these templates, a homology model 
was constructed spanning residues 39–329, including the 
20 amino acid long Gly-Ser linker. The model was truncated 
at residue 285 as residues 286–329 were poorly modeled. 
The structure for HER2 was available (PDB-ID: 1N8Z).21 As a 
note, the 1N8Z-structure contains residues 23–629, resulting 
in a difference in numbering between 1N8Z and the HER2 
precursor protein sequence (uniprot P04626). A homolo-
gous structure for CD19 was identified using BioInfoBank 
meta server.49 A model for residues 1–272 of CD19 was con-
structed with Modeller V9.1 using 3MJG (12.59% sequence 
identity) as a structural template.22
Initially, pairwise docking was performed with PatchDock23 
using the individual TanCAR domains and the correspond-
ing receptor; residues 39–155 corresponded to the HER2 
binding portion of TanCAR, whereas residues 156–285 were 
assigned to the CD19 binding portion of TanCAR. Fits were 
evaluated visually and based on their PatchDock score. For 
the TanCAR-HER2 docking, results were additionally filtered 
based on peptide spotting experiments that had suggested 
binding residues (Supplementary Figure S1). Further 
refinement of the individual candidate dockings was done 
using FireDock.24 Candidate dockings from both CAR-HER2 
and CAR-CD19 were then combined in UCSF Chimera29 and 
evaluated for steric clashes. The final model for the CD19-
CAR-HER2 docking was selected based on lowest global 
energy in each of the pairwise dockings from FireDock and 
steric constraints in the entire assembly.
Construction, delivery, and expression of the TanCAR-
encoding transgene. The CD19-specific scFv was provided 
by Heddy Zola (Women’s and Children’s Hospital, Adelaide, 
Australia).50 The HER2-specific scFv, FRP5, was previously 
described by Wels and colleagues.51 The modeled bispe-
cific extracellular domain was assembled on Clone Manager 
(Sci-Ed Software, Cary, NC). The designed transgene DNA 
sequence was modified to include restriction enzyme sites at 
the cloning sites and exclude any inadvertently inserted sites 
within the translation elements, then optimized using the 
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GeneOptimizer software for maximum protein production.26 
The TanCAR extracellular domain was then synthesized by 
GeneArt Inc. using oligonucleotides, cloned into the Gate-
way entry vector pDONR221, and sequence verified. This 
antigen recognition domain was then subcloned in frame into 
an SFG retroviral vector containing a short hinge, and the 
transmembrane and signaling domain of the costimulatory 
molecule, CD28 and the signaling domain of the T cell recep-
tor ζ-chain (Figure 3a). The structure of the construct was 
confirmed using restriction digests. The 5′-3′ as well as the 
3′-5′ sequence of the whole construct was confirmed using 
single base pair pyro-sequencing (SeqWright DNA-Technol-
ogy, Houston, TX) with >97% homology with the optimized 
construct map.
Retrovirus production and transduction of T cells. To produce 
retroviral supernatant, human embryonic kidney (HEK) 293T 
cells were cotransfected with the TanCAR-encoding retrovi-
ral transfer plasmid, Peg-Pam-e plasmid encoding MoMLV 
gag-pol, and plasmid pMEVSVg containing the sequence 
for VSV-G envelope,28 using GeneJuice transfection reagent 
(EMD Biosciences, San Diego, CA).28 Supernatants contain-
ing retroviral vector were collected 48 and 72 hours later.
Anti-CD3(OKT3)/anti-CD28 activated T cells were 
 transduced with retroviral vectors as described.19 Briefly, 
peripheral blood mononuclear cells were isolated by Lympho-
prep (Bio-One, Monroe, NC) then activated with OKT3 (Ortho-
Biotech, Raritan, NJ) and CD28 monoclonal  antibodies (BD 
Biosciences, Palo Alto, CA) at a final  concentration of 1 µg/ml. 
On day 2, recombinant human IL-2 (Chiron, Emeryville, CA) 
was added at a final concentration of 100 U/ml, and 2 days 
later, cells were harvested for retroviral transduction over 
recombinant fibronectin fragment (Takara-Bio-USA, Madison, 
WI) pre-coated plates. Subsequently, 3 × 105 T cells per well 
were transduced with retrovirus in the presence of 100 U/ml 
IL-2. After 48–72 hours cells were removed and expanded in 
the presence of 50–100 U/ml IL-2 for 10–15 days before use.
Cytotoxicity assays. Cytotoxicity assays were performed 
as previously described.19 Briefly, 1 × 106 target cells were 
labeled with 0.1 mCi (3.7 MBq) 51Cr and mixed with decreas-
ing numbers of effector cells to give effector to target ratios of 
40:1, 20:1, 10:1, and 5:1. Target cells incubated in complete 
medium alone or in 1% Triton X-100 were used to determine 
spontaneous and maximum 51Cr release, respectively. After 4 
hours, we collected supernatants and measured radioactivity 
in a gamma counter (Cobra Quantum; PerkinElmer; Welles-
ley, MA). The mean percentage of specific lysis of triplicate 
wells was calculated according to the following formula: (test 
release − spontaneous release)/(maximal release − sponta-
neous release) × 100.
Analysis of cytokine production and T cell expansion. Effec-
tor T cells (TanCAR-expressing T cells or non-transduced T 
cells) from healthy volunteers were cocultured with tumor 
cells in short-term culture, HER2-positive and HER2-nega-
tive cell lines, at various effector to target ratios in a 24 well 
plate. After 24 to 48 hours incubation, culture supernatants 
were harvested and the presence of IFN-γ and IL-2 was 
determined by ELISA as per the manufacturer’s instructions 
(R&D Systems, Minneapolis, MN). T cell expansion was 
determined by counting viable cells (trypan blue exclusion) 7 
days after stimulation.
Tetracycline-inducible system. To express the truncated 
CD19 (thereafter referred to as CD19) on Daoy cells, we 
used the Tet-On 3G Tetracycline-Inducible Expression Sys-
tem (CloneTech, Mountainview, CA). The CD19 encoding 
DNA fragment was subcloned downstream of the induc-
ible promoter P
TRE3G using PCR amplification. Daoy cells 
expressed CD19, but only when cultured in the presence of 
doxycycline (DOX+), a tetracycline analog. When bound by 
doxycycline, the Tet-On 3G protein undergoes a conforma-
tional change that allows it to bind to tet operator sequences 
located in the inducible promoter PTRE3G. The addition of 
doxycycline also initiated a proportionate expression of the 
reporter gene mCherry.
Flow cytometry. A FACScalibur instrument (Becton Dickin-
son, Mountain View, CA) and CellQuest software (BD Bio-
sciences) were used. Analysis was done on >10,000 events. 
Negative controls included isotype antibodies. Cells were 
incubated 15–30 minutes with antibodies at 4 °C in the dark 
then washed and fixed in 0.5% paraformaldehyde before 
analysis. Surface expression of the TanCAR exodomain 
was assessed using a HER2-scFv (FRP5)-specific method 
by incubation with a soluble HER2.Fc fragment followed by 
Fc-specific FITC-labeled antibody. Alternatively, APC-conju-
gated Fab-specific antibody was used to detect either HER2-
scFv or CD19-scFv.
Animal studies. All animal experiments were conducted on 
a protocol approved by the BCM Institutional Animal Care 
and Use Committee. Male recipient NOD-SCID mice of 8–10 
weeks old (FOX CHASE CB-17 SCID ICR; Taconic, Hudson, 
NY) were anesthetized with isofluorane (Abbott Laboratories, 
Abbott Park, IL) and received a subcutaneous injection of 
1 × 106 DAOY.TET.CD19 cells (in 100 µl PBS) per flank per 
mouse. Tumors were then allowed ~3 weeks to fully engraft. 
Mice with established tumors (mean tumor volume 94 µl: SD 
28 µl) were randomly assigned to four groups (n = 5 tumors/
group). Tumor volume was calculated from the product of the 
bidimensional area measured with an electronic caliper. All 
four groups of animals had similar tumor volumes after ran-
domization. To induce the expression of CD19 (DOX+) two 
groups received intraperitoneally 80 µg/mouse daily for 1 
week followed thrice-weekly doses thereafter. The other half 
received an equal volume of PBS (DOX−) on the same dos-
ing schedule. On the third day of doxycycline/PBS adminis-
tration, within the DOX+ and DOX− groups, 5 animals each 
received one intratumoral injection of 10,000 TanCAR T cells 
per µl tumor volume. All mice were then blindly assessed for 
fold changes in tumor volume.
Immunofluorescence. Staining for CD19 was performed on 
Daoy.DOX.CD19 explants in the presence or absence dox-
ycycline. Sections were deparaffinized in xylene and rehy-
drated in decreasing concentrations of ethanol. For antigen 
retrieval, slides were immersed in DAKO Citrate Buffer in 
a pressure cooker for 45 minutes. After blocking with 5% 
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donkey serum, tissues were incubated with CD19 primary 
antibody at 4°C overnight in a humidified chamber and with 
secondary anti-rabbit antibody at room temperature for 1 
hour. Samples were counterstained with DAPI and examined 
under a fluorescent microscope.
Statistical analysis. The two-tailed Student’s t-test was used 
to test for significance in each set of values, assuming equal 
variance. Mean values ±SD are given unless otherwise 
stated. Kaplan–Meier analysis was used to assess survival 
of experimental animal groups.
Supplementary material
Figure S1. Binding of anti-HER2 antibody FRP5 to peptide 
arrays.
Figure S2. Surface expression of the TanCAR was tested 
using two different methods.
Figure S3. We used a tetracycline-inducible system to con-
ditionally express a truncated non-signaling CD19 molecule 
on Daoy cells (Daoy.TET.CD19).30
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